Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Hisamitsu Pharmaceutical Co's average EPS without NRIGrowth Rate was 10.50% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 22.70% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 21.90% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was -0.40% per year.
During the past 13 years, Hisamitsu Pharmaceutical Co's highest 3-Year average EPS without NRI Growth Rate was 28.60% per year. The lowest was -21.70% per year. And the median was 1.70% per year.
Hisamitsu Pharmaceutical Co (FSE:4530) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Hisamitsu Pharmaceutical Co Earnings per Share (Diluted) Related Terms
Hisamitsu Pharmaceutical Co Earnings per Share (Diluted) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hisamitsu Pharmaceutical Co Earnings per Share (Diluted) Chart
FSE:4530 vs AMPH, ESPR, NIKA: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hisamitsu Pharmaceutical Co PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's PE Ratio distribution charts can be found below:
* The bar in red indicates where Hisamitsu Pharmaceutical Co's PE Ratio falls into.
Hisamitsu Pharmaceutical Co Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Hisamitsu Pharmaceutical Co's Earnings Per Share (Diluted) for the fiscal year that ended in Feb. 2026 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円268.56
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of 円268.56 mean?
Hisamitsu Pharmaceutical Co (FSE:4530) has a Earnings per Share (Diluted) of 円268.56 as of Nov. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Hisamitsu Pharmaceutical Co and its competitors. According to the industry distribution chart, Hisamitsu Pharmaceutical Co ranks #239 out of 788 companies in the Drug Manufacturers industry, placing it in the top 30.3%.
Is Hisamitsu Pharmaceutical Co's Earnings per Share (Diluted) too high?
Hisamitsu Pharmaceutical Co's current Earnings per Share (Diluted) is 円268.56. Based on the distribution chart, Hisamitsu Pharmaceutical Co ranks #239 out of 788 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Earnings per Share (Diluted) compare to AMPH and ESPR?
According to the Drug Manufacturers industry distribution chart, Hisamitsu Pharmaceutical Co ranks #239 out of 788 companies for Earnings per Share (Diluted). This puts Hisamitsu Pharmaceutical Co in the upper half of its industry. The industry median Earnings per Share (Diluted) is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.60, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Hisamitsu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hisamitsu Pharmaceutical Co's current Earnings per Share (Diluted) is 円268.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current Earnings per Share (Diluted) of 円268.56. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current Earnings per Share (Diluted) is 円268.56. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current Earnings per Share (Diluted) is 円268.56 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.
Key valuation signals for FSE:4530:
Earnings per Share (Diluted): 円268.56
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score
Get the complete analysis for FSE:4530
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4530 has been successfully added to your 
